Arun Mannem, MD
Hospitalist · Saint Louis, MONPI 1871721019
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 307 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 32.7% of the total. 2025 is the largest year on record at $1,752, 2.3 times the $758 reported in 2019. Among hospitalist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 307 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$553
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$492
- Bristol Myers Squibb$349
- Ardelyx, Inc.$256
- Takeda Pharmaceuticals U.S.A., Inc.$252
- plus $2K from 25 others
What the payments were for
- Consulting fees$180%
- Food & beverage$5,635100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 120 | $1,848 |
| Johnson & Johnson | 27 | $553 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $492 |
| Bristol Myers Squibb | 19 | $349 |
| Ardelyx, Inc. | 10 | $256 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $252 |
| Pfizer | 11 | $239 |
| Ironwood Pharmaceuticals, Inc | 9 | $190 |
| Gilead | 9 | $188 |
| Enterra Medical, Inc. | 2 | $187 |
| Sanofi | 8 | $172 |
| Daiichi Sankyo Inc. | 7 | $127 |
| Braintree Laboratories, Inc. | 6 | $93 |
| Medtronic | 2 | $82 |
| Merck | 5 | $82 |
| Ipsen Biopharmaceuticals, Inc | 3 | $77 |
| QOL Medical, LLC | 3 | $73 |
| Nestle Healthcare Nutrition Inc. | 2 | $57 |
| Celltrion USA Inc. | 3 | $55 |
| Madrigal Pharmaceuticals | 2 | $46 |
| Novo Nordisk | 2 | $37 |
| AstraZeneca | 2 | $30 |
| UCB, Inc. | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Mirum Pharmaceuticals, Inc. | 1 | $19 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
| Sandoz | 1 | $18 |
| Boehringer Ingelheim | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IBSRELA$112
How this compares
$5,654 in reported general payments places this provider in the 95th percentile of 712 hospitalist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 21 | $574,995 |
| LinzessLinaclotide | 61 | $36,430 |
| Mesalamine | 29 | $18,336 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 44 | $3,054 |
| Colestipol Hcl | 30 | $2,828 |
| Dicyclomine Hcl | 76 | $1,969 |
| Pantoprazole Sodium | 107 | $1,342 |
| Lansoprazole | 15 | $1,058 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 47 | $997 |
| Esomeprazole Magnesium | 35 | $995 |
| CholestyramineCholestyramine (With Sugar) | 15 | $992 |
| Omeprazole | 128 | $856 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 12 | $472 |
| Mirtazapine | 18 | $326 |
| Famotidine | 46 | $319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $553 | $574,99521 claims |
| AbbVieLinzess | $1,848 | $36,43061 claims |
| SandozLansoprazole | $18 | $1,05815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 712 hospitalist providers in Missouri.
Other hospitalist in Saint Louis
- Gian MusarraSaint Louis$25K
- Ghassan DaherSaint Louis$23K
- Marsha SchulteSaint Louis$23K
- Ijeoma NwelueSaint Louis$12K
- Vasanthan KuppuswamySaint Louis$5K
- Yamuna KondapallySaint Louis$5K
- Basem AbdeenSaint Louis$4K
- John MwangiSaint Louis$4K
- Emily WoodSaint Louis$3K
- Tariq HalasaSaint Louis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.